Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 5Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Intraocular Lymphoma 2Thymoma 1Stomach Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Recurrence 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1

Interventions

Cetuximab 11Cisplatin 10Radiotherapy 8Docetaxel 8Erlotinib Hydrochloride 7Paclitaxel 6Gemcitabine 6Chemotherapy, Adjuvant 6Immunohistochemistry 5Sorafenib 4Radiosurgery 4Carboplatin 4Capecitabine 4Biopsy 4sargramostim 3Vorinostat 3Trastuzumab 3Surgical Procedures, Operative 3Radiotherapy, Intensity-Modulated 3Nivolumab 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3Filgrastim 3Doxorubicin 3Bevacizumab 3ixabepilone 2aldesleukin 2Taxes 2SS1(dsFv)PE38 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Salivary Gland Neoplasms × MK 2206 × Clear all
NCT01604772 2019-05-01

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 7 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡